Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
CRISPR Therapeutics AG Logo

ARKG Holdings of CRISPR Therapeutics (CRSP) - Updated Daily

Lock IconJoin Premium Plan
The Bucket Report Icon
Download ARK WatchlistsDownload ARK holdings as watchlists that can be imported into TradingView and Interactive Brokers
Date
Direction
Shares
Fund Weight
Fund
March 1, 2022BUY33.671k0.0497%ARKG
January 20, 2022BUY61.494k0.1033%ARKG
January 5, 2022BUY9.800k0.0137%ARKG
December 30, 2021BUY10.000k0.0158%ARKG
December 29, 2021BUY14.400k0.0215%ARKG

Key Statistics

DateMay 09, 2022Revenue
Expected0
Actual$940.00k
EPS
Expected-$1.94
Actual-$2.32
🕵🏼Found In🏷Last Price
ARKKARKG$56.34
⚖️Weighting🧢Market Cap
4.3%$4.36b
🏋🏿‍♂️Weight Rank In ARKG🧮Price to Sales
44.77
🏋️‍♀️Weight Rank Across All Funds🌏Country
10🇨🇭Switzerland
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$70.062.53%
Description
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
Website
crisprtx.com